| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) through any online brokerage.
Other companies in Zentalis Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Zentalis Pharmaceuticals has a consensus price target of $8.63.
The stock price for Zentalis Pharmaceuticals (NASDAQ: ZNTL) is $2.3619 last updated October 21, 2026 at 6:34 PM EDT.
There are no upcoming dividends for Zentalis Pharmaceuticals.
Zentalis Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Zentalis Pharmaceuticals.
Zentalis Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
